CIK 0001544227 · Non-accelerated filer<br>Smaller reporting company
Tempest Therapeutics, Inc.
Sign in to watch- Ticker
- TPST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 451472564
- Phone
- 415-798-8589
- Business address
- 2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE, CA, 94005
- Former names
- Millendo Therapeutics, Inc., OvaScience, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-13 | Frederick John W. Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2026-09-22 | Smith Nancy Freda Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2026-06-04 | Yee John D. Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2026-06-04 | Richey William Drake Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2026-03-31 | Trojanowski Justin Corporate Controller | Grant or award · Employee Stock Option (right to buy) | +22,000 | 22,000 | ||
| 2026-03-31 | Maestas Nicholas Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2026-03-24 | Angel Matthew CEO and President | Purchase | +231,482 | $2.16 | $500K | 231,482 |
| 2026-03-24 | Angel Matthew CEO and President | Purchase · Series A Warrant (right to buy) | +231,482 | 231,482 | ||
| 2026-03-24 | Angel Matthew CEO and President | Purchase · Series B Warrant (right to buy) | +231,482 | 231,482 | ||
| 2026-03-24 | Angel Matthew CEO and President | Purchase | +231,482 | $2.16 | $500K | 231,482 |
| 2026-02-04 | Angel Matthew CEO and President | Grant or award · Employee Stock Option (right to buy) | +269,621 | 269,621 | ||
| 2026-01-27 | Simantov Ronit Director | Grant or award · Stock Option (right to buy) | +1,230 | 1,230 | ||
| 2026-01-27 | RAAB MICHAEL Director | Grant or award · Stock Option (right to buy) | +1,230 | 1,230 | ||
| 2026-01-27 | NICHOL GEOFFREY Director | Grant or award · Stock Option (right to buy) | +1,230 | 1,230 | ||
| 2026-01-27 | Pellizzari Christine A Director | Grant or award · Stock Option (right to buy) | +1,230 | 1,230 | ||
| 2025-01-02 | Trojanowski Justin Corporate Controller | Grant or award · Employee Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2025-01-02 | Brady Stephen R President and CEO | Grant or award · Employee Stock Option (right to buy) | +550,000 | 550,000 | ||
| 2025-01-02 | Whiting Samuel Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +270,000 | 270,000 | ||
| 2025-01-02 | Maestas Nicholas Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2024-08-12 | Versant Venture Capital VI, L.P. 10% owner | Sale | −387,999 | $1.10 | $427K | 209,941 |
Page 1 of 6 · 119 trades